Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2213
Source ID: NCT00330330
Associated Drug: Isis 113715
Title: Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: ISIS 113715
Outcome Measures: Primary: To evaluate the safety and tolerability of ISIS 113715|To evaluate the pharmacokinetic profile of ISIS 113715|To evaluate the pharmacologic activity of ISIS 113715 |
Sponsor/Collaborators: Sponsor: Ionis Pharmaceuticals, Inc.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 96
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
Start Date: 2003-02
Completion Date: 2006-08
Results First Posted:
Last Update Posted: 2008-02-06
Locations: NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny, Bialystok, 15-435, Poland|Prywatna Praktyka Lekarska, Radom, 26-600, Poland|Oddzial Chorob Wewnetrznych ze Stacja Dializ Szpital w Wolominie, Wolomin, 05-200, Poland|Chair of Endocrinology and Diabetology of the Faculty of Advenced Training for Physicians, Moscow, 109125, Russian Federation|Endocrinology Scientific Centre of RAMS, Moscow, 117036, Russian Federation|Medical Institution "Polyclinic OAOA Gazprom", Moscow, 117420, Russian Federation|Close Corporation "MEDSI", Moscow, 123056, Russian Federation|Chair of Endocrinology and Diabetology Central Clinical Hospital of the Ministry of Communications of RF, Moscow, 125315, Russian Federation|Moscow Regional Scientific-Research Clinical Institute named after I.F. Vladimirsky, Moscow, 129110, Russian Federation|Clinic of Therapy of Postgraduate Education named after N.S. Molchanov, St. Petersburg, 198013, Russian Federation
URL: https://clinicaltrials.gov/show/NCT00330330